Who We Are
Oyster Venture Partners consists of a multi-disciplinary team of highly experienced operational deal makers who have worked across the biotechnology, therapeutic, diagnostic, medical technology, digital healthcare and healthcare
sectors around the globe. Our culture centres on closely partnering our client base, throughout the capital raising process supporting all levels of experienced leaders with a wide range of funding and corporate transactions.
The Team
Rupert Lewis
CEO
David D’Alton
Chairman
Kaarel Aulik
Analyst
Dr Gilles Devillers
Venture Advisor
Dr Kris Motmans, PhD
Venture Partner
Carl Weir
Venture Partner
pharmaceutical and biotech
industry. A scientific, engineering
and business background in
negotiation, strategic marketing,
drug delivery, pharma and
biotechnology.
Serial advisor and innovator with a track record of business & digital transformation, product strategy and advisory across finance, legal, AI, ML, Big Data, blockchain, payments, and digital healthcare.
To be appointed
Chief Technology Officer
Experienced CTO in healthtech with a background of delivering technology infrastructure across the sector.
Rupert Lewis
CEO
E: rupert.lewis@oystervp.com
David D’Alton
Chairman
E: david.dalton@oystervp.com
30+ years international business development and capital raising experience across the life science spectrum. Lead Partner with the UK Government’s Department of International Trade (DIT) Life Sciences Organisation (LSO)
Kaarel Aulik
Analyst
E: kaarel.aulik@oystervp.com
Dr Gilles Devillers
Venture Advisor
pharmaceutical and biotech
industry. A scientific, engineering
and business background in
negotiation, strategic marketing,
drug delivery, pharma and
biotechnology.
To be appointed
Chief Technology Officer
Experienced CTO in healthtech with a background of delivering technology infrastructure across the sector.
Dr Kris Motmans, PhD
Venture Partner and Chief Scientific Investment Officer